tiprankstipranks
Defence Therapeutics Launches Convertible Debenture Offering
Company Announcements

Defence Therapeutics Launches Convertible Debenture Offering

Story Highlights

Defence Therapeutics (TSE:DTC) has released an update.

Don't Miss Our Christmas Offers:

Defence Therapeutics, a Canadian biopharmaceutical firm, has announced the offering of new unsecured convertible debentures aimed at raising up to CAD$1,570,000. These debentures, offering an 8% interest rate, are convertible into common shares, potentially resulting in the issuance of over 2.6 million shares. This financial move is part of the company’s strategy to settle outstanding debt while continuing to advance its innovative biopharmaceutical technologies.

For further insights into TSE:DTC stock, check out TipRanks’ Stock Analysis page.

Related Articles
TipRanks Canadian Auto-Generated NewsdeskDefence Therapeutics Strengthens Leadership with Key Appointments
TipRanks Canadian Auto-Generated NewsdeskIC Capitalight Reports New Exploration Results
TipRanks Canadian Auto-Generated NewsdeskDefence Therapeutics to License Accum Technology
Looking for investment ideas? Subscribe to our Smart Investor newsletter for weekly expert stock picks!
Get real-time notifications on news & analysis, curated for your stock watchlist. Download the TipRanks app today! Get the App